Consent to Disclosure

On behalf of Pharmacia & Upjohn Company, I hereby consent to disclosure of the following documents by the United States Food and Drug Administration (FDA) to the Institute of Medicine at the National Academy of Science (IOM) for the purpose of performing an independent review of the data. I understand that the documents as disclosed to IOM may contain trade secrets and confidential commercial or financial information within the meaning of 18 U.S.C. 1905, 21 U.S.C. 331(j) and 5 U.S.C. 552(b)(4) and agree to hold FDA harmless for any injury caused by FDA's disclosing the documents to IOM. IOM is authorized to include any portion of any document so disclosed, as well as any description or summary of any document so disclosed, in a report to be made available to the public by IOM at the conclusion of the independent review.

Documents to be disclosed:

NDA Clinical Trial Data

  1. FDA's medical reviews of the NDA

  2. Complete study reports (Upjohn) for the three pivotal premarketing studies (6024, 6045, 6041)

  3. Complete study reports (Upjohn) for the three major postmarketing studies (0366, 0373, 0235)

  4. Case report forms/line listings for the clinical trials (i.e., new data)

1992 Re-Analysis

  1. FDA Report on the Database remake and re-analysis of 1992

Annual Reports

  1. The last 10 annual reports for the NDA

1996 Task Force Report

  1. The task force report (including Dr. Williams' regulatory history of the NDA)

Statistics & Epidemiology

  1. All reports on Halcion from FDA Office of Epidemiology & Biostatistics

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement